On Demand Webinar

Translational In Vitro & In Vivo Models for KRAS-Targeted Therapeutic Development

KRAS remains one of the most prominent and challenging oncogenic drivers in solid tumors, with mutations such as KRAS G12C, G12D, and G12V representing critical therapeutic targets in cancers including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Developing effective interventions against these variants demands robust, clinically relevant research models.

In this 30-minute expert-led webinar, Rajendra Kumari, PhD explores Crown Bioscience’s advanced in vitro and in vivo translational platforms for targeting KRAS-mutant cancers.

Watch a preview:

Discover how our systems replicate the complexity of KRAS-driven tumor biology—empowering drug screening, mechanistic studies, and translational research to accelerate therapeutic development.

Dr. Kumari highlights both cell-based and animal model platforms.

You'll learn about:

Core Preclinical in vitro and in vivo models: From isogenic cell systems and patient-derived organoids to PDXs, GEMMs, and humanized mouse models covering diverse KRAS mutations (G12C/D/V/Q61) and co-mutations
Advanced Tools for Mechanistic & Translational Insight: Leveraging advanced patient-derived systems that preserve genetic fidelity, clinical heterogeneity and TME with CRISPR engineering, organoid drug screening, proteomics, spatial biology, and biomarker platforms to map resistance, pathway rewiring, and target engagement
Seamless translation of preclinical findings into clinical strategies: Data-driven design of KRAS inhibitor combinations (SHP2, EGFR, DDR, IO) supported by models that predict efficacy, overcome resistance, and guide indication and biomarker selection.

Whether you are working on direct KRAS inhibitors, targeting downstream signaling pathways (e.g., MEK, ERK), or designing rational drug combinations, this webinar will offer essential guidance for selecting the right model systems.

About The Presenter:

Rajendra Kumari, PhD, Executive Director, Integrated Solutions, Crown Bioscience

As Executive Director of Integrated Solutions, Rajendra leads the focus of cross-disciplinary solutions for drug discovery and development. She has over 20 years of oncology research experience with a Ph.D. in Molecular Pharmacology from the University of Leicester (UK). Prior to joining Crown Bioscience, Rajendra held post-doctoral fellowships and an Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham, where she developed in vitro and in vivo preclinical models, including patient-derived systems and imaging capabilities. Rajendra also co-founded PRECOS Ltd. in 2010, serving as COO and then following the merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. In 2018, Rajendra became the Global Head of Scientific Communications for all platforms at Crown Bioscience Inc., working closely with multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications and chairs Crown Bioscience's Global Scientific Committee.